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TABLE 1 Baseline and Post-Procedural Characteristics (n ¼ 44)
Clinical variables
Age, yrs 77.9  6.8
Female 7 (15.9)
Diabetes mellitus 10 (22.7)
COPD 13 (29.5)
Prior myocardial infarction 8 (18.2)
Neurological dysfunction 4 (9.1)
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93Transcatheter Aortic
Valve Replacement for
Severe Aortic Stenosis
Patients Undergoing
Chronic DialysisPVD 19 (43.2)
Prior cardiac surgery 8 (18.2)
Porcelain aorta 7 (15.9)
Prior PCI 16 (36.4)
Prior balloon aortic valvuloplasty 8 (18.2)
Critical preoperative state 5 (11.4)
NYHA functional class III/IV 31 (70.5)
Frailty score 2–3 14 (31.8)
Logistic EuroSCORE I 13.3 (8.4–26.3)
Post-procedure
Permanent pacemaker implantation 9 (20.5)
Myocardial infarction 0 (0)
Major vascular complications 0 (0)
Stroke 0 (0)
Transfusions 11 (26.2)
Number of units 2.1  1.7
Infections 1 (2.3)
In-hospital mortality 2 (4.5)
Follow-up
30-day mortality 4 (9.1)
1-year mortality 15 (34.1)
1-year MACCE 16 (36.4)
1-year rehospitalization 21 (47.7)
Values are mean  SD, n (%), or median (interquartile range).
COPD ¼ chronic obstructive pulmonary disease; MACCE ¼major adverse cardiac
and cerebrovascular event(s); NYHA ¼ New York Heart Association; PCI ¼
percutaneous coronary intervention; PVD ¼ peripheral vascular disease.Aortic stenosis (AS) is common in patients with end-
stage renal disease and the rate of progression
is faster than in patients without end-stage renal
disease. While aortic valve replacement (AVR) is
the gold-standard approach for patients with symp-
tomatic severe AS, surgical AVR (SAVR) carries
considerable risks, which are maximized in elderly
patients and in those with signiﬁcant comorbidities.
Indeed, patients with chronic dialysis undergoing
SAVR have poor short- and long-term outcomes (1).
Transcatheter aortic valve replacement (TAVR) has
emerged as a therapeutic option for high- and
prohibitive-risk patients (2). However, dialysis pa-
tients were excluded from previous clinical trials,
largely limiting the understanding of this novel
therapy in this particular patient subset (2). We
report, therefore, the outcomes of TAVR in patients
with chronic dialysis from the large multicenter
Italian OBSERVANT (OBservational Study of Effec-
tiveness of AVR—TAVI procedures for severe Aortic
steNosis Treatment) Registry, the results of which
have been partly published elsewhere (3).
Between December 2010 and June 2012, a total of
7,618 consecutive patients with severe AS undergo-
ing either TAVR (n ¼ 1,911) or SAVR (n ¼ 5,707) at 95
Italian centers were prospectively enrolled in the
OBSERVANT Registry. The Local Ethics Committee of
the principal investigation site approved the registry.
The patients gave consent to use their data for sci-
entiﬁc purposes and in an anonymous form. Patient
eligibility criteria, registry design, and data collec-
tion modalities have been previously described (3).
All outcomes were adjudicated through a linkage
with administrative databases. Throughout the study
period, TAVR was performed in 44 dialysis patients
(2.3% of TAVR population). Baseline and follow-up
characteristics are listed in Table 1. Mean age was
77.9  6.8 years of age, patients were commonly men
(74.1%), severely symptomatic (New York Heart As-
sociation functional class III/IV, 70.5%), and frail
(Geriatric Status Scale 2 to 3, 31.8%). The median
logistic EuroSCORE I was 13.3% (interquartile range
[IQR]: 8.4% to 26.3%). Moreover, a certain amount
of patients had prior cardiac intervention such ascardiac surgery (18.2%), percutaneous coronary
intervention (36.4%), and balloon aortic valvulo-
plasty (18.2%). Mean left ventricular ejection fraction
was 48.2  12.9%. Pulmonary hypertension (i.e.,
estimated pulmonary artery systolic pressure
>60 mm Hg) and moderate/severe mitral regurgita-
tion were frequently observed (22.7% and 36.4%,
respectively). Approach sites were 77.3% trans-
femoral, 9.1% transaxillary, and 11.4% transapical
and most of the cases were performed under local
anesthesia (68.2%). In terms of device selection,
63.6% received the third-generation self-expanding
transcatheter heart valve (THV) (CoreValve ReValv-
ing System, Medtronic Inc., Minneapolis, Minnesota)
and 36.4% the balloon-expandable THVs (Edwards
Sapien XT, Edwards Lifesciences, Irvine, California).
The distribution of implanted valve sizes was 23 mm
(3.6%), 26 mm (28.6%), 29 mm (53.6%), and 31 mm
(14.3%) for the self-expanding valves, and 23 mm
Letters J A C C V O L . 6 6 , N O . 1 , 2 0 1 5
J U L Y 7 , 2 0 1 5 : 9 1 – 9
94(31.3%), 26 mm (37.5%), and 29 mm (31.3%) for the
balloon-expanding valves. Two self-expanding
valves were implanted in 1 patient (2.3%). The
mean sheath size was 18.8  2.1-F.
After the procedure, the mean aortic valve gradient
was reduced from 46.8  13.0 mm Hg at baseline to
9.3  4.0 mm Hg (D37.4  12.3 mm Hg; p < 0.001 for
paired echocardiograms), whereas moderate/severe
paravalvular regurgitation and new permanent pace-
maker implantation were observed in 12.2% and
20.5% of the patients, respectively. The median
length of intensive care unit and hospital stays was
relatively short (2.0 [IQR: 1.0 to 4.0] days and 6.0
[IQR: 5.0 to 8.0] days, respectively). In-hospital and
30-day mortality was 4.5% and 9.1%, respectively.
The median follow-up was 503 days (IQR: 155 to
808 days), and no patient was lost to follow-up. One-
year mortality was 34.1%. One-year rates of major
adverse cardiac and cerebrovascular event and reho-
spitalization were 36.4% and 47.7%, respectively.
To our knowledge, this is the largest multicenter
report on the results of early and mid-term outcome
of TAVR in chronic dialysis patients. The 30-day
mortality of 9.1% in our study is comparable with
the 30-day mortality of 7.6% and 9.7% in the overall
population in the Transcatheter Valve Therapy Reg-
istries (Sapien THV), as well as in the FRANCE-2 reg-
istry (both Sapien and CoreValve THV), respectively
(4,5); therefore, considering the severe comorbidity
and frailty of our patients, our results further support
performing TAVR in this complex setting. In addition,
shorter intensive care unit and hospital stays would
be a great advantage for these high-risk and frail pa-
tients. Highly calciﬁed aorta (i.e., porcelain aorta) and
iliofemoral vessels are major concerns in patients
with chronic dialysis. In this study, however, neither
stroke nor major vascular complications (i.e., need
of surgical or endovascular intervention) occurred in
the TAVR group. Conversely, 1-year mortality in
our study was higher than that in the FRANCE-2
registry (34.1% vs. 24%), demonstrating the high
cardiovascular risk proﬁle in this subgroup. While a
large sample size was initially included, the relatively
limited number of dialysis patients precluded deﬁn-
itive conclusions. Our initial ﬁndings, as well as the
most appropriate therapy (i.e., TAVR or SAVR) for
severe AS patients with dialysis warrant future
investigation.
In conclusion, our preliminary experience utilizing
data from a large multicenter registry suggests in a
mid-term follow-up, favorable safety, and efﬁcacy
of TAVR in patients with severe AS and chronic
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Trimethylamine-N-Oxide
and Heart FailureThe new study by Tang et al. (1) demonstrating an
inverse correlation of serum levels of trimethylamine-
N-oxide (TMAO) with survival in patients with heart
failure (HF) is intriguing and thought provoking.
Similar ﬁndings have been published recently by
Norwegian researchers.
In our judgment, TMAO is more likely to be a
marker than a mediator in this relationship. Fish,
